Tonix Pharmaceuticals Holding Corp. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
Dec. 31, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 – SUBSEQUENT EVENTS On February 14, 2019, the Company granted options to purchase an aggregate of 10,000 shares of the Company’s common stock to a director with an exercise price of $1.86, with a term of ten years, vesting on the date of the Corporation’s 2019 annual meeting of shareholders. On February 26, 2019, the Company granted options to purchase an aggregate of 62,040 shares of the Company’s common stock to employees with an exercise price of $1.89, with a term of ten years, vesting 1/3 on the first anniversary and 1/36th each month thereafter for 24 months. Additionally, the Company granted options to purchase 41,360 shares of the Company’s common stock to employees with an exercise price of $2.36, with a term of ten years, vesting 1/3 on the first anniversary and 1/36th each month thereafter for 24 months.

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2018

NOTE 11 – SUBSEQUENT EVENTS

On February 14, 2019, the Company granted options to purchase an aggregate of 10,000 shares of the Company’s common stock to a director with an exercise price of $1.86, with a term of ten years, vesting on the date of the Corporation’s 2019 annual meeting of shareholders.

On February 26, 2019, the Company granted options to purchase an aggregate of 62,040 shares of the Company’s common stock to employees with an exercise price of $1.89, with a term of ten years, vesting 1/3 on the first anniversary and 1/36th each month thereafter for 24 months. Additionally, the Company granted options to purchase 41,360 shares of the Company’s common stock to employees with an exercise price of $2.36, with a term of ten years, vesting 1/3 on the first anniversary and 1/36th each month thereafter for 24 months.